@article{7cbd1e87ac504c559ab5acccfb1f5068,
title = "Drug resistance and BCR-ABL kinase domain mutations in philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement",
abstract = "Patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) frequently relapse on imatinib with acquisition of BCR-ABL kinase domain (KD) mutations. To analyze the changes that second-generation tyrosine kinase inhibitors (TKIs) have brought in mutation frequency and type, a database review was undertaken of the results of all the BCR-ABL KD mutation analyses performed in the authors' laboratory from January 2004 to January 2013.",
keywords = "BCR-ABL mutations, acute lymphoblastic leukemia, dasatinib, imatinib, resistance, BCR-ABL mutations, acute lymphoblastic leukemia, dasatinib, imatinib, resistance",
author = "Simona Soverini and {De Benedittis}, Caterina and Cristina Papayannidis and Stefania Paolini and Claudia Venturi and Ilaria Iacobucci and Mario Luppi and Paola Bresciani and Marzia Salvucci and Domenico Russo and Simona Sica and Ester Orlandi and Tamara Intermesoli and Antonella Gozzini and Massimiliano Bonifacio and Rigolin, {Gian Matteo} and Fabrizio Pane and Michele Baccarani and Michele Cavo and Giovanni Martinelli",
year = "2013",
doi = "10.1002/cncr.28522",
language = "English",
volume = "2013",
pages = "N/A--N/A",
journal = "Cancer",
issn = "0008-543X",
publisher = "River Street:Hoboken, NJ John Wiley & Sons Incorporated",
}